Tesamorelin
FDA ApprovedTesamorelin
- Category
- Growth Hormone
- Aliases
- Egrifta, Egrifta SV
- Administration
- Subcutaneous injection (once daily)
Documented benefits
Tier 1 · Peer-reviewed / regulatoryBenefit categories
Growth Hormone
Tesamorelin's defining research application — the only growth hormone-stimulating peptide in this database with a current FDA-approved label.
Fat loss
Its FDA-approved effect specifically targets visceral fat, more selectively than general growth hormone elevation.
IGF-1 elevation
Stimulates pulsatile, physiologic growth hormone release, which drives IGF-1 production via the liver.